INDUSTRIAL IMPACT

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Envisagenics | December 05, 2022 | Read time : 02:00 min

Envisagenics Announces
Envisagenics, an Artificial Intelligence driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb. The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.

SpliceCore, a cloud-based, AI-powered platform, can identify disease-specific splicing-derived targets by using RNA-sequencing data.  Envisagenics will integrate data from thousands of patients to identify mRNAs encoding for tumor-specific cell surface antigens, thereby fostering the discovery of novel targets to enable development of therapeutics.

"It is exciting to see how quickly significant scientific breakthroughs in the biopharma industry can be achieved with the assistance of AI. Our SpliceCore platform, coupled with Bristol Myers Squibb's expertise, has the potential to accelerate target identification, transform modern drug development, and improve patient outcomes."

Maria Luisa Pineda, Ph.D., Envisagenics' CEO and Co-founder

The SpliceCore platform applies an ensemble of proprietary algorithms to RNA-sequencing data, creating a sequence search space of approximately 7 million splicing events, thus maximizing the odds of drug target discovery. SpliceCore prioritizes drug targets based on their disease-specificity, biological roles, and druggability through a variety of drug modalities. Thanks to its scalable and cost-effective cloud architecture, the platform can process massive amounts of RNA-seq data efficiently and at high speed. SpliceCore helps to identify drug targets quickly and, in turn, predicts drug-responding alternative splicing events for therapeutic development.

Martin Akerman, Ph.D., Envisagenics' CTO and Co-founder, added, "novel therapeutic targets are urgently needed for patients, and Envisagenics is thrilled to be collaborating with BMS as part of our quest for innovation."

About Envisagenics
Envisagenics is an Artificial Intelligence-driven biotechnology company that focuses on the discovery of novel RNA splicing variants that cause cancer and other genetic diseases. Its principal technology is the SpliceCore® discovery platform. The platform re-envisions the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing. It is up to 250 times more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing events that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders.

Envisagenics partners with biopharmaceutical companies and academic institutions to advance their drug discovery capabilities. Envisagenics also has its own internally developed RNA therapeutic programs. Envisagenics is a spin-out of Cold Spring Harbor Laboratory and a proud woman- and minority-led recipient of several grants from the National Institute of General Medical Sciences and the National Cancer Institute.

Spotlight

Created in 1997, the association is the French non-profit organization that brings together the country's leading innovative health compagnies and their expert partners.

Spotlight

Created in 1997, the association is the French non-profit organization that brings together the country's leading innovative health compagnies and their expert partners.

Related News

CELL AND GENE THERAPY

Casma Therapeutics Raises $46.0 M in Series C Funding

Casma Therapeutics, Inc. | November 21, 2022

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment. Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also participated in the financing. Dr. Hiromichi Kimura, Investment Director of Astellas Ventures, has joined the board of directors. Dr. Tomotaka Okino of Ono Venture Investment and Amgen Ventures have joined as board observers. Casma will use proceeds to advance its lead program for MYD88 mutant lymphoma through preclinical and into IND enabling studies. “The closing of this financing has strengthened our resources to continue advancing our drug pipeline focused on autophagy-based degradation. We are thrilled to welcome several top-tier investors who recognize the potential of our biological platforms and therapeutic assets targeting well-known high-value and traditionally undruggable targets.” Keith Dionne, Ph.D., Chief Executive Officer of Casma Therapeutics, Inc "Casma’s autophagy-based degradation platform, PHLYT™, is unique and impressive,” commented Dr. Kimura. “Along with a rich pipeline of autophagy degraders, the company has also established a highly qualified team with extensive scientific experience in drug development. We expect that this round of funding will accelerate development of Casma’s pipeline assets, especially its degrader for MYD88 mutant tumors.” About Casma Therapeutics, Inc. Casma Therapeutics, Inc. is developing novel cellular degradation approaches based on the autophagy pathway to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery targets large and complex disease targets such as organelles, protein aggregates and large signaling complexes and before directing them to the lysosome for elimination. By selectively degrading disease targets by autophagy, Casma expects to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration, and metabolic disorders.

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Evaxion Earns FDA fast-track Designation for Personalized Cancer Immunotherapy

Evaxion Biotech A/S | January 23, 2023

Evaxion Biotech A/S, a leading clinical-stage biotechnology firm focused on the development of AI-driven immunotherapies, recently announced that FDA has granted fast-track designation for the Company's customized cancer therapy, EVX-01, in conjunction with KEYTRUDA®. In December 2022, Evaxion gained FDA clearance to proceed with its phase 2b clinical test, where patients with metastatic melanoma are given EVX-01 in combination with KEYTRUDA®. In addition, Evaxion obtained fast-track designation for the vaccine candidate on January 17, 2023. The fast track is developed to expedite FDA's assessment of innovative, novel medications with the potential to meet an unfulfilled medical need. EVX-01, a peptide-based immunotherapy for cancer, is Evaxion's most advanced clinical asset. The program generates a unique medicine for each patient based on gene analysis of their malignancies and matching with their immune system. The Company's proprietary AI platform, PIONEER, helps facilitate this process. Per Norlén, CEO at Evaxion, commented," We are extremely pleased that our cancer vaccine candidate EVX-01 has received the FDA fast track designation, as it enables a potentially faster approval of the vaccine. This is first and foremost to the benefit of the patients. And it is a great validation of our AI platform, PIONEER, and our drug development candidate." (Source – Globe Newswire) The ongoing Phase 2b clinical trial is being done at sites in Europe, the United States, and Australia. It is conducted in partnership with Merck, which supplies its PD-1 inhibitor KEYTRUDA®. The trial was launched in Australia when the first patient was enrolled in September 2022. About Evaxion Biotech A/S Evaxion is a clinical-stage AI-immunology™ platform company using AI, engineering expertise and drug development knowledge to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. It has utilized artificial intelligence to build a diverse pipeline of candidate immunotherapies that target two of the most critical unmet medical needs in the world, cancer and infectious diseases. Its three proprietary AI platforms include PIONEER, EDEN and RAVEN.

Read More

AI, INDUSTRIAL IMPACT

Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH

Cimeio | December 12, 2022

The two studies demonstrate proof-of-concept that genetically engineered variants of cell surface receptors harboring single amino acid substitutions are fully functional but evade a paired immunotherapy directed against the wild-type molecule. This technology will enable the development of more efficient and safer targeted conditioning regimens for hematopoietic stem cell transplantation, gene therapies, and opens the path to more efficient cell and immunotherapy-based treatment approaches for hematological malignancies. The first abstract was titled “Function-preserving single amino acid substitutions shield hematopoietic stem and progenitor cells from CD117 targeted immunotherapy in vivo.” The receptor tyrosine kinase c-KIT is expressed on normal hematopoietic stem cells but also on leukemia cells. Consequently, it is an attractive target for an antibody-based conditioning therapy. The study showed that cells expressing a genetically engineered variant of CD117 are fully functional in vitro and contributed to the blood development in vivo, similar to unmodified HSCs expressing the wt receptor. Mice transplanted with a mix of human HSCs expressing either wt CD117 or the Cimeio shielded CD117 variant showed a selective depletion of wt CD117 cells, while those cells expressing the variant receptor were spared following the treatment with a monoclonal antibody directed against wt CD117. The second abstract, titled “Engineered Single Amino Acid Substitutions Protect Hematopoietic Stem and Progenitor Cells From CD123 Targeted Immunotherapy,” focused on targeting the interleukin-3 receptor alpha-chain a cytokine receptor highly expressed on various hematological malignancies as well as normal hematopoietic cells. This abstract demonstrated that shielded CD123 cells were not depleted by a highly efficient CD123 targeted immunotherapy. Collectively, these preclinical studies demonstrate the feasibility and efficacy of Cimeio’s SCIP platform, a novel and promising therapeutic approach to improve the outcomes for patients with benign and malignant hematological diseases in need of an HSC transplant. “Many severe and late side effects following an HSC transplant are caused by untargeted and broadly toxic chemotherapeutics and radiation in conditioning regimens. The presented work is an encouraging and important step towards safer and efficient approaches to overcome these hurdles. Cimeio’s SCIP platform could allow more patients facing debilitating and fatal diseases to receive a life-saving HSC transplant.” Suneet Agarwal, M.D., Ph.D., Co-Program Leader for the Stem Cell Transplant Center at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Associate Professor of Pediatrics at the Harvard Medical School, and member of the Cimeio Scientific Advisory Board Last month, Cimeio announced the issuance of a foundational patent that covers a method for in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells, the basis of its SCIP platform. About Cimeio Cimeio is an applied gene editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ which has the potential to transform hematopoietic stem cell transplant. Cimeio’s technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

Read More